Tracy Harbut, MD | |
15 Medical Park Drive Ne, Suite 301, Cartersville, GA 30121 | |
(404) 920-4950 | |
Not Available |
Full Name | Tracy Harbut |
---|---|
Gender | Female |
Speciality | Pain Medicine - Interventional Pain Medicine |
Location | 15 Medical Park Drive Ne, Cartersville, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689108078 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | R4628 (Kentucky) | Secondary |
208VP0014X | Pain Medicine - Interventional Pain Medicine | 92889 (Georgia) | Primary |
Entity Name | Interventional Spine And Pain Management Center, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518012004 PECOS PAC ID: 2769483031 Enrollment ID: O20070130000066 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Approximately 66 percent of respondents to a Maryland telephone survey do not have advance medical directives, according to a new report by researchers from the Johns Hopkins Bloomberg School of Public Health's Department of Health Policy and Management.
The usual way of cultivating cells is to use a flat laboratory dish of glass. However, inside a human body, the cells do not grow on a flat surface, but rather in three dimensions. This has lead researchers at Lund University in Sweden to develop a porous "spaghetti" of tissue-friendly polymers with cavities in which the cells can develop in a more natural way.
Patients with obstructive sleep apnea (OSA) may blame their daytime difficulties on simple sleepiness, but new research suggests that their brains may be to blame. Specifically, their cognitive challenges may be caused by structural deficits in gray matter, brought on by the intermittent oxygen deprivation that comes with OSA. The good news is that these deficits may be partially or fully reversible with early detection and treatment, according to Italian researchers
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Tracy Harbut, MD 3390 Peachtree Rd Ne Ste 1500, Atlanta, GA 30326-2822 Ph: (404) 920-4950 | Tracy Harbut, MD 15 Medical Park Drive Ne, Suite 301, Cartersville, GA 30121 Ph: (404) 920-4950 |
News Archive
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Approximately 66 percent of respondents to a Maryland telephone survey do not have advance medical directives, according to a new report by researchers from the Johns Hopkins Bloomberg School of Public Health's Department of Health Policy and Management.
The usual way of cultivating cells is to use a flat laboratory dish of glass. However, inside a human body, the cells do not grow on a flat surface, but rather in three dimensions. This has lead researchers at Lund University in Sweden to develop a porous "spaghetti" of tissue-friendly polymers with cavities in which the cells can develop in a more natural way.
Patients with obstructive sleep apnea (OSA) may blame their daytime difficulties on simple sleepiness, but new research suggests that their brains may be to blame. Specifically, their cognitive challenges may be caused by structural deficits in gray matter, brought on by the intermittent oxygen deprivation that comes with OSA. The good news is that these deficits may be partially or fully reversible with early detection and treatment, according to Italian researchers
› Verified 8 days ago